US20120029937A1 - Dialysis device - Google Patents
Dialysis device Download PDFInfo
- Publication number
- US20120029937A1 US20120029937A1 US13/260,456 US201013260456A US2012029937A1 US 20120029937 A1 US20120029937 A1 US 20120029937A1 US 201013260456 A US201013260456 A US 201013260456A US 2012029937 A1 US2012029937 A1 US 2012029937A1
- Authority
- US
- United States
- Prior art keywords
- treatment
- settings
- dialysis device
- session
- option
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1601—Control or regulation
- A61M1/1613—Profiling or modelling of patient or predicted treatment evolution or outcome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3607—Regulation parameters
- A61M1/3609—Physical characteristics of the blood, e.g. haematocrit, urea
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3379—Masses, volumes, levels of fluids in reservoirs, flow rates
- A61M2205/3393—Masses, volumes, levels of fluids in reservoirs, flow rates by weighing the reservoir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/502—User interfaces, e.g. screens or keyboards
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/502—User interfaces, e.g. screens or keyboards
- A61M2205/505—Touch-screens; Virtual keyboard or keypads; Virtual buttons; Soft keys; Mouse touches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/20—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
Definitions
- the present invention concerns the field of dialysis treatment. It relates more particularly to a dialysis device comprising an automated peritoneal dialysis machine or a hemodialysis machine that, based on input of certain data, is programmed to carry out a treatment session.
- Treatment of a patient with renal insufficiency is typically carried out according to a treatment plan created by a prescriber, such as a physician, based on certain therapeutic objectives.
- the treatment plan may comprise a schedule of treatment sessions and specific settings for each scheduled treatment session.
- the treatment plan typically also includes dietary advice, medications, frequency of blood samples for follow-up etc.
- Treatment of renal insufficiency typically takes place in individual treatment sessions.
- One session may have duration between 1 and 12 hours.
- Certain conditions may effect the actual execution of the treatment plan and the resulting treatment.
- One condition may be related to modifications of the treatment settings according to the wish of the patient. Such a modification may typically be the extension or shortening of duration of the treatment session.
- Another condition may be related to changes due to clinical conditions such as limited achievable blood flow, unexpectedly high weight gain, technical failure or a hypotensive episode.
- a further condition may be related to the actual result of a preceding treatment session.
- a number of dialysis devices are known (see, for example, U.S. Pat. No. 5,326,476) in which the treatment parameters (duration, flow rate, etc.) are programmed by a prescriber such as a physician or a technician.
- the devices of the prior art are limited to verifying the desired modification.
- This may be achieved by means of a dialysis device comprising a prescriber interface and a programming means configured to allow, via the prescriber interface, input of a set of therapeutic objectives and a treatment plan and a re-evaluation means configured to, as a function of the therapeutic objectives and the treatment plan, suggest at least one treatment option comprising a set of settings of a treatment session to achieve said set of therapeutic objectives.
- the treatment plan defined by the prescriber is generally intended for a period or a number, n, of consecutive treatment sessions.
- the set of settings comprises a number of individual settings wherein the individual setting may be duration of treatment session, blood flow, fluid removal rate, total removed fluid volume, dialysis fluid composition, dialysis fluid flow rate, dialysis fluid temperature, dialyzer type, treatment session schedule, number of exchanges per session, frequency of exchanges, fluid volume per exchange, duration of each dwell and glucose concentration in dialysis fluid.
- An individual therapeutic or clinical parameter may be creatinine clearance, Kt/V ratio, ultrafiltration, sodium elimination, weight of the patient, total body water or blood pressure.
- a treatment option would typically comprise a set of settings for a treatment session that together will result in reaching the therapeutic objectives.
- the dialysis device comprises a patient interface and a modification means configured to allow, via the patient interface, modification of at least one of said settings wherein the re-evaluation means is configured to, as a function of the modified setting, suggest the at least one treatment option.
- the dialysis device is configured to suggest at least one treatment option including the modified setting(s) where one or several other settings of the session have been changed as a consequence of the setting(s) modified according to the patient's wishes.
- One setting modified by the patient may result in several suggested treatment options since a modification may be compensated for in several different ways.
- the patient may modify settings during an ongoing treatment session.
- at least one treatment option may be offered at the consecutive session or sessions.
- the dialysis device comprises a condition-determining means that is configured to measure clinical or therapeutic parameters wherein the re-evaluation means is configured to, as a function of the measured parameters during an on-going treatment session or measured parameters of at least one preceding treatment session, suggest the at least one treatment option.
- the re-evaluation means is configured to suggest the at least one treatment option as a function of the modified setting via the patient interface and the parameters measured by means of the condition-determining means.
- the patient interface is configured to allow the patient to select one of the suggested treatment options whereby the dialysis device adjusts the settings in consequence of the selection to carry out the treatment session in accordance with the selected treatment option.
- the patient interface is configured to display an indication of the result of the treatment in relation to the set of therapeutic objectives as measured by means of the condition-determining means.
- the result of the treatment in relation to the set of therapeutic objectives may be graphically displayed in the form of a graph, bar chart or an indicator gauge.
- the main indication offered to the patient at the end of each treatment and/or at the start of programming may be a percentage attainment of the objectives, e.g. with a percentage figure of 85% signifying that the patient is in deficit by 15% relative to the therapeutic objectives thus visualizing adequacy of the treatment as a whole or each of the parameters indicative of the adequacy of the treatment.
- the programming means is configured to allow input, via the prescriber interface, limits of variation of each of the at least one setting that are allowed to be modified via the patient interface thereby allowing modification of each setting within these limits.
- a modification of a setting may result in that the patient is advised to accept a certain treatment option rather than one of several options.
- the programming means may also be configured to allow input, via the prescriber interface, of limits of variation of the measured clinical or therapeutic parameters.
- the dialysis machine comprises an alert means configured to issue an alert upon a deviation above or below a predefined limit of variation of a measured clinical or therapeutic parameter.
- the patient interface comprises a display configured to display the at least one suggested treatment option.
- the display means being functionally linked to the re-evaluation means.
- the patient interface and/or the prescriber interface is comprised by a graphical user interface.
- the graphical user interface is a touch screen.
- the dialysis device comprises a prescriber interface and a programming means configured to allow, via the prescriber interface, input of a set of therapeutic objectives and a treatment plan and a condition-determining means that is configured to measure clinical or therapeutic parameters during an ongoing or resulting from a treatment session wherein the patient interface is configured to display the result of the treatment in relation to the set of therapeutic objectives as measured by means of the condition-determining means.
- the patient is requested to respond to very specific clinical questions before modifying his treatment. Such responses may prevent the modification of said treatment.
- This set up may be referred to as a decision tree.
- the decision tree may also take into account information from recorded and/or measured parameters in order to better orient the patient and/or the treatment options as a function of the details gathered with the aid of these questions.
- the responses given by the patient will be communicated to the prescriber in the context of a medical monitoring of the patient after a reasonable time or, if appropriate, immediately, depending on the possible consequences on the state of health or therapeutic monitoring of the patient.
- the dialysis device comprises an automated peritoneal dialysis machine also referred to as a cycler.
- the dialysis device comprises a hemodialysis machine.
- the dialysis device according to the invention may be used advantageously in the context of home peritoneal dialysis and home hemodialysis respectively.
- the dialysis device in the form of a hemodialysis machine may be used in a clinic or a self care setting.
- the dialysis treatment is performed by introducing dialysis fluid into the peritoneal cavity of a patient.
- the dialysis takes place over the peritoneum.
- the used dialysis fluid is drained from the peritoneal cavity and fresh dialysis fluid may be entered for continued treatment either directly or with a time delay.
- the dialysis fluid is usually available as a sterilized bagged fluid. For a treatment session during e.g. 8 hours multiple bags of fluid are used.
- the peritoneal dialysis machine in a cyclic manner assists in filling the peritoneum with fresh dialysis fluid from one bag at the time, possibly via a heater bag for heating the dialysis fluid to body temperature, and after a period of dwell draining the peritoneum and transferring the used dialysis fluid to a drain bag or to a drain.
- the dialysis device By means of the dialysis device according to the present invention it is possible to provide for an optimized use of the available fluids as a function of the duration of the treatment session.
- various treatment settings may be modified by the patient.
- the therapeutic objectives to be reached over a period of n sessions may include one or more of the following: beta-2-microglobuline clearance, creatinine clearance, urea clearance, urea reduction ratio (URR), Kt/V ratio, sodium elimination, ultrafiltration volume, ultrafiltration rate, weight of the patient, blood chemistry parameters, haemoglobin and blood pressure.
- the blood chemistry parameters may include serum levels of phosphate, sodium, calcium, potassium, bicarbonate, albumin, urea or creatinine.
- the at least one suggested treatment option for a period of n consecutive treatment sessions is advantageously adapted to the parameters measured during the preceding m treatment sessions.
- Such parameters may be measured by the condition-determining means e.g. in the form of an ultrafiltration measurement means, a patient scale, blood samples or a means for analysis of effluent (drained dialysis fluid).
- the patient's glucose level may also be monitored during the treatment session by means of the condition-determining means. It is also possible to measure the glucose level in the drained dialysis fluid.
- the parameters measured during the preceding m treatment sessions include one or more of the following measurements: change in patient's weight, change in patient's blood pressure, change in patient's fat mass, quantity and nature of patient's food intake, quantity of water absorbed by patient, effective ultra-filtration, temperature of patient, physical strength of patient, residual renal function, urea removal, creatinine removal, change in blood parameters such as sodium, phosphate, calcium.
- the number n of consecutive peritoneal dialysis treatment sessions may be performed during a period lasting between 3 and 30 days, e.g. 7 days.
- the number m of preceding peritoneal dialysis treatment sessions may have been performed during a period lasting between 3 and 30 days, e.g. 7 days.
- a compensation of a treatment result is achieved by requiring the patient, for a consecutive treatment session, to correct the effects of the preceding sessions, limiting the freedom of modification.
- the patient is preferably forced to choose from at least one of the following constraints: minimum duration of treatment, modification of the dialysis fluid composition or combination of dialysis fluid compositions, modification to the number of exchange cycles or to the exchange volume, modification of water intake between treatment sessions, addition of further exchange sessions during the day, or modification of the dialysis fluid composition used during these exchanges.
- medical personnel responsible for the treatment of the patient is informed automatically by an alert when a deviation above or below a predefined limit is detected in relation to the therapeutic objectives that have been defined for the patient.
- the information may be transferred to the medical personnel remotely, for example by telephone or by Internet link.
- a deviation of ⁇ 30% over a 24-hour period may be accepted, provided that the weekly objective of, for example, 7 litres of ultrafiltration and 70 litres of creatinine clearance is achieved.
- the Kt/V objective may be 2.3.
- the prescriber may take into account the filtration surface of the patient's membrane, its transport quality (high, medium or low), the residual renal function, and the body mass and clinical parameters such as weight, blood pressure and total body water when designing the treatment plan.
- the prescriber in cooperation with the dialysis device configured for performing peritoneal dialysis defines the rules forming basis for the treatment options suggested by the re-evaluation means.
- the ultrafiltration falls below 700 ml on one day, a modification of the glucose or sodium concentration of the dialysis fluid and/or the addition of other colloidal osmotic pressure solutions during the treatment and/or the daily exchange or exchanges will be suggested as a treatment option by the re-evaluation means.
- the estimated clearance on account of the reduced duration of the exchanges from 12 hours to 8 hours one night, drops by more than 30%, increase the number of exchanges the following night or prolong the duration of the treatment session from 10 hours to 13 hours, or else add supplementary daytime exchange sessions.
- the patient may vary the duration of the treatment session from one day to another.
- the device may permit programming a duration of a treatment session of between 8 and 12 hours in normal time, or of between 10 and 14 hours if it registers a cumulative therapeutic deficit due to treatment sessions that are too short in the last few days, or of a minimum of 14 hours if this deficit is deemed to be too great, or may even propose a supplementary daytime treatment session.
- the other parameter on which the patient may act is the water/sodium intake and/or the ultrafiltration in case of weight gain. Such intake or ultrafiltration parameters may as well form part of a suggested treatment option.
- the treatment may be carried out e.g. in a clinic where the patient is assisted by e.g. by a nurse, in a self care setting or at a patient's home.
- the treatment of a patient with renal insufficiency is carried out according to a treatment plan created by a prescriber.
- the therapeutic objectives for a hemodialysis treatment typically include dialysis dose per unit of time, the patients so called “dry weight” and target ranges for various blood parameters.
- the “dry weight” is the weight at which the patient should be at the end of the treatment, that is, after fluid removal. Blood parameters of importance may be blood pressure, hematocrit, serum phosphate, serum potassium, serum sodium etc.
- a target range is specified for each parameter.
- the dialysis dose may be specified for each treatment, e.g. as URR (Urea Reduction Ratio) or spKt/V (Single Pool Kt/V) or similar, or for a longer time, e.g. weekly stdKt/V (Weekly Standard Kt/V).
- the treatment schedule may be specified as one treatment session thrice weekly for a fixed period of time, typically 3-5 hours. Alternatively a treatment session may be scheduled every other day (i.e. 3.5 times per week), daily (i.e. 5-6 times per week, typically 2 hours) or during the night while sleeping, often referred to as nocturnal treatment (e.g. 3-6 times per week).
- the treatment schedule may be anything between these schedules, or a mix of two or more schedules, e.g. a mix of short daily and nocturnal treatments.
- Settings defining each treatment session comprises e.g. dialyzer type, dialysis fluid composition, dialysis fluid temperature, dialysis fluid flow rate, target blood flow and treatment duration.
- the targeted weight loss is entered for each treatment session. The targeted weight loss is based on how much the patient weighs before treatment and knowledge of the prescribed dry weight.
- the prescriber may also set limits on allowed variation for each resulting setting.
- the limits are chosen by the prescriber to be safe for the patient, yet allow flexibility in how the individual dialysis treatment sessions are performed.
- the prescriber may set a maximum allowed weight loss rate of 800 ml/min, to avoid hypotension which is a potentially dangerous condition.
- the target blood parameters and the dialysis fluid composition have been left out for simplicity.
- the parameters disclosed serves to illustrate the second aspect of the invention.
- the data representing the therapeutic objectives, the treatment plan (including schedule of treatments and session settings) and variation limits are entered into a programming means of the hemodialysis machine, via a prescriber interface.
- the prescriber interface may form part of the hemodialysis machine itself.
- the dialysis device comprises several parts such that the prescriber interface is separate from the dialysis machine itself.
- a home dialysis device comprises two separate components; a computer system at the clinic and the hemodialysis machine in the patient's home.
- the computer system at the clinic comprises the prescriber interface, where the prescriber enters the treatment plan.
- the treatment plan may be electronically transferred to the hemodialysis machine, e.g. via a portable electronic media such as a USB memory or via a direct electronic connection by telephone line or internet. Once the treatment plan is transferred to the hemodialysis machine the treatment may commence without further changes.
- One embodiment of the second aspect of the invention is related to dialysis treatment performed in an in-center setting where the patient is assisted by a physician or a nurse.
- each hemodialysis machine will serve several patients.
- the dialysis device for the in-center setting may comprise a single computer system for the whole clinic and several hemodialysis machines.
- the treatment plan for each patient is stored on the computer system until the patient to be treated has been assigned to a specific hemodialysis machine.
- the therapeutic objectives and/or the treatment plan may be transferred to the hemodialysis machine via an electronic network. Alternatively the therapeutic objectives and the treatment plan may be transferred to the hemodialysis machine from a personal portable memory device, such as a USB memory or an electronic patient card.
- the re-evaluation means will suggest at least one treatment option and the treatment may commence without further changes once one of these options is selected via the patient interface.
- the patient interface allows for modifications of any of the resulting treatment settings.
- Reasonable modifications to the settings is allowed to be made via the patient interface, i.e. modifications are allowed as long as they are within limits set by the prescriber e.g. the duration of a treatment session may be set between 3 and 7 hours and it will not be possible to enter a duration of treatment session outside these limits.
- Patient B may want to shorten the duration of the treatment session from 5 to 4 hours on a particular day. If this new duration of treatment is within the set limits the modification is allowed.
- the re-evaluation means determines how other treatment settings may be changed to achieve the therapeutic objectives and suggests at least one treatment option.
- the re-evaluation means may also take into account other available data of the patient such as the treatment history and current treatment parameters when suggesting new treatment options to achieve the therapeutic objectives.
- the maximum allowed weight loss rate may have been set to 800 g/hour, in which case the maximum total weight loss that may be achieved in the prescribed 2.5 hour treatment is 2.0 kg.
- the re-evaluation means suggests a treatment option where the duration of the treatment is prolonged to 3 hours and 45 minutes, which allows the dry weight to be reached while maintaining a safe weight removal rate.
- the re-evaluation means may suggest a second treatment option, where a weight loss of only 2.0 kg in the current treatment session is reached, leaving a “debt” until the next treatment session.
- the maximum blood flow that may be achieved is 300 ml/min due to that the needles have been somewhat misplaced during cannulation. This is lower than the blood flow of 350 ml/min according to the entered treatment plan.
- the re-evaluation means suggests a treatment option showing an increase of the dialysis fluid flow rate from 500 to 800 ml/min. If increase of dialysis fluid flow is not sufficient to reach the treatment dose objective, additionally the re-evaluation means will suggest a treatment option where the treatment time is extended. Alternatively, the re-evaluation means may suggest a treatment option resulting in that a dose “debt” is left for the next treatment session or treatment sessions.
- the patient interface displays a list including at least one setting that may be modified.
- Patient B in the example above decides that an extension of treatment time of 15 minutes is acceptable, then he/she sets the treatment time to be 5 hours and 15 minutes—and the re-evaluation means dynamically shows how high the dialysis fluid flow has to be to reach the treatment dose target. Once the user has decided that the suggested combination of parameters are acceptable, they are accepted via the patient interface and the hemodialysis machine dynamically makes the necessary adjustments.
- the hemodialysis machine comprises a condition-measuring means providing data so as to determine how well the therapeutic objectives are reached.
- Some therapeutic objectives are possible to measure or estimate e.g. the dialysis dose, which may be measured using blood samples analyzed for BUN (Blood Urea Nitrogen), or estimated using on-line clearance estimating technology.
- the re-evaluation means may take into account measurements conducted by the condition-measuring means when suggesting treatment options to achieve the therapeutic objective of the treatment dose. Parameters such as plasma phosphate content may be evaluated by means of blood samples in order to follow up how well therapeutic objectives on such parameters are achieved. Results of blood sample analysis is preferably entered into a treatment history record whereby the re-evaluation means may be configured to use the patient history data for suggesting consecutive treatment options.
- the re-evaluation means takes into account the treatment history as well as several future treatment sessions when suggesting a treatment option, as will be described below.
- this requires storing treatment history of each patient.
- the treatment history may be stored in the memory comprised by the control system of the hemodialysis machine, since it is being used by a single patient.
- the treatment history of each patient has to be stored either on the clinic computer system (e.g. via network) or on a personal portable memory device.
- the data representing the patient history would typically include data related to previous treatment sessions (time and date, duration, blood flow or blood volume processed, fluid flow, dialysis fluid composition, weight loss, achieved online clearance etc) and possibly also indicators of therapeutic objectives (achieved dialysis dose, pre-dialysis weight, blood parameters such as pressure, haemoglobin, etc).
- the patient history to be taken into account typically comprises the treatment sessions during 7 preceding days.
- the re-evaluation means would suggest a treatment option having longer treatment duration. If the weight loss debt is significant, the re-evaluation means may suggest a treatment option where the weight is removed over several future treatment sessions.
- This treatment option may comprise increasing dialysis fluid flow, increasing blood flow, increasing time or choosing a different dialyzer with a larger membrane surface area.
- Patient A knows that he will have limited time for treatment tomorrow, he may choose to increase duration of the treatment session today, for example from 2.5 hours to 3.5 hours. This will increase the dialysis dose today and thus put him/her ahead of schedule in achieving the weekly dose target. The re-evaluation means will then suggest a shorter time for the treatment tomorrow.
- Examples VI and VII indicate that the patient may be below as well as above a therapeutic objective, in these examples the weekly dialysis dose target.
- the patient interface according to the invention therefore includes an indicator that in a simple and understandable fashion shows how well the therapeutic objectives are reached. This may be in the shape of a percentage figure, e.g. 85%, or a graphical representation such as a bar graph.
- the achievement of therapeutic objectives may also be shown over time, e.g. by a diagram with time on the horizontal axis. For example, if the therapeutic objective is the weekly dialysis dose, the graph may display the target as a horizontal line, and the actually achieved dose may be represented as connected points, where each point represents the achieved weekly dose over the last 7 days.
- the dialysis device may comprise a condition-determining means configured to measure parameters relevant for the therapeutic objective.
- the condition-determining means may comprise e.g. an online clearance estimating device, a blood pressure monitor, a blood composition analyser, a patient scale.
- the condition-determining means may be configured to detect failure to meet the therapeutic objectives and to issue an alert to the patient (via the patient interface) and/or to the prescriber via e.g. telephone line or internet connection.
- All of the steps, as well as any sub-sequence of steps, described above may be controlled by means of a programmed computer apparatus forming part of the dialysis device.
- a programmed computer apparatus forming part of the dialysis device.
- the embodiments of the invention described above comprise computer apparatus and processes performed in computer apparatus, the invention thus also extends to computer programs, particularly computer programs on or in a carrier, adapted for putting the invention into practice.
- the program may be in the form of source code, object code, a code intermediate source and object code such as in partially compiled form, or in any other form suitable for use in the implementation of the procedure according to the invention.
- the program may either be a part of an operating system, or be a separate application.
- the carrier may be any entity or device capable of carrying the program.
- the carrier may comprise a storage medium, such as a Flash memory, a ROM (Read Only Memory), for example a DVD (Digital Video/Versatile Disk), a CD (Compact Disc), an EPROM (Erasable Programmable Read-Only Memory), an EEPROM (Electrically Erasable Programmable Read-Only Memory), or a magnetic recording medium, for example a floppy disc or a hard disc.
- the carrier may be a transmissible carrier such as an electrical or optical signal which may be conveyed via electrical or optical cable or by radio or by other means.
- the carrier may be constituted by such cable or device or means.
- the carrier may be an integrated circuit in which the program is embedded, the integrated circuit being adapted for performing, or for use in the performance of, the relevant procedures.
Abstract
A dialysis device comprising a prescriber interface and a programming means configured to allow, via the prescriber interface, input of a set of therapeutic objectives and a treatment plan and a re-evaluation means configured to, as a function of the therapeutic objectives and the treatment plan, suggest at least one treatment option comprising a set of settings of a treatment session to achieve said set of therapeutic objectives.
Description
- The present invention concerns the field of dialysis treatment. It relates more particularly to a dialysis device comprising an automated peritoneal dialysis machine or a hemodialysis machine that, based on input of certain data, is programmed to carry out a treatment session.
- Treatment of a patient with renal insufficiency is typically carried out according to a treatment plan created by a prescriber, such as a physician, based on certain therapeutic objectives. The treatment plan may comprise a schedule of treatment sessions and specific settings for each scheduled treatment session. The treatment plan typically also includes dietary advice, medications, frequency of blood samples for follow-up etc.
- Treatment of renal insufficiency typically takes place in individual treatment sessions. One session may have duration between 1 and 12 hours.
- Certain conditions may effect the actual execution of the treatment plan and the resulting treatment. One condition may be related to modifications of the treatment settings according to the wish of the patient. Such a modification may typically be the extension or shortening of duration of the treatment session. Another condition may be related to changes due to clinical conditions such as limited achievable blood flow, unexpectedly high weight gain, technical failure or a hypotensive episode. A further condition may be related to the actual result of a preceding treatment session.
- A number of dialysis devices are known (see, for example, U.S. Pat. No. 5,326,476) in which the treatment parameters (duration, flow rate, etc.) are programmed by a prescriber such as a physician or a technician.
- There are also devices (see, for example, U.S. Pat. No. 5,788,851) which are designed to allow a patient, or even a member of the patient's family assisting the patient, to interact with the programming of the treatment. In such devices, the interaction between patient and device is effected via an interface, for example implemented on a touch screen.
- However, the devices provided with a patient interface, such as are described in the prior art, are not programmed in such a way as to define therapeutic or clinical objectives to be achieved, for example a predefined creatinine clearance value, a given dose defined as a Kt/V ratio where K=clearance of urea (ml/min), t=time on dialysis (min), V=volume of urea distribution in the body (ml), an individualized water removal target, a sodium balance.
- Moreover, if treatment settings are modified by the patient, the devices of the prior art are limited to verifying the desired modification.
- There is therefore a need to provide a dialysis device and a method where certain data inputs e.g. in the form of treatment session settings, results in at least one suggested treatment option securing that the therapeutic objectives initially fixed by the prescriber are achieved.
- It is an object of the present invention to at least partly overcome one or more of the above identified limitations of prior art. Specifically it is an object to provide an improved dialysis device securing that a treatment objective is reached while allowing flexibility in the individual treatment sessions. This may be achieved by means of a dialysis device comprising a prescriber interface and a programming means configured to allow, via the prescriber interface, input of a set of therapeutic objectives and a treatment plan and a re-evaluation means configured to, as a function of the therapeutic objectives and the treatment plan, suggest at least one treatment option comprising a set of settings of a treatment session to achieve said set of therapeutic objectives.
- The treatment plan defined by the prescriber is generally intended for a period or a number, n, of consecutive treatment sessions.
- The set of settings comprises a number of individual settings wherein the individual setting may be duration of treatment session, blood flow, fluid removal rate, total removed fluid volume, dialysis fluid composition, dialysis fluid flow rate, dialysis fluid temperature, dialyzer type, treatment session schedule, number of exchanges per session, frequency of exchanges, fluid volume per exchange, duration of each dwell and glucose concentration in dialysis fluid.
- An individual therapeutic or clinical parameter may be creatinine clearance, Kt/V ratio, ultrafiltration, sodium elimination, weight of the patient, total body water or blood pressure.
- A treatment option would typically comprise a set of settings for a treatment session that together will result in reaching the therapeutic objectives.
- In one embodiment of the invention the dialysis device comprises a patient interface and a modification means configured to allow, via the patient interface, modification of at least one of said settings wherein the re-evaluation means is configured to, as a function of the modified setting, suggest the at least one treatment option.
- Various settings may be modified in accordance with the patient's wishes. The dialysis device is configured to suggest at least one treatment option including the modified setting(s) where one or several other settings of the session have been changed as a consequence of the setting(s) modified according to the patient's wishes. One setting modified by the patient may result in several suggested treatment options since a modification may be compensated for in several different ways.
- In one embodiment of the invention the patient may modify settings during an ongoing treatment session. In this case as a consequence of the modifications, at least one treatment option may be offered at the consecutive session or sessions.
- In one embodiment of the invention the dialysis device comprises a condition-determining means that is configured to measure clinical or therapeutic parameters wherein the re-evaluation means is configured to, as a function of the measured parameters during an on-going treatment session or measured parameters of at least one preceding treatment session, suggest the at least one treatment option. In another embodiment of the invention the re-evaluation means is configured to suggest the at least one treatment option as a function of the modified setting via the patient interface and the parameters measured by means of the condition-determining means.
- According to a further embodiment of the invention the patient interface is configured to allow the patient to select one of the suggested treatment options whereby the dialysis device adjusts the settings in consequence of the selection to carry out the treatment session in accordance with the selected treatment option.
- In one embodiment of the invention the patient interface is configured to display an indication of the result of the treatment in relation to the set of therapeutic objectives as measured by means of the condition-determining means. The result of the treatment in relation to the set of therapeutic objectives may be graphically displayed in the form of a graph, bar chart or an indicator gauge.
- The main indication offered to the patient at the end of each treatment and/or at the start of programming may be a percentage attainment of the objectives, e.g. with a percentage figure of 85% signifying that the patient is in deficit by 15% relative to the therapeutic objectives thus visualizing adequacy of the treatment as a whole or each of the parameters indicative of the adequacy of the treatment.
- In a further embodiment of the invention the programming means is configured to allow input, via the prescriber interface, limits of variation of each of the at least one setting that are allowed to be modified via the patient interface thereby allowing modification of each setting within these limits.
- In one embodiment of the invention a modification of a setting may result in that the patient is advised to accept a certain treatment option rather than one of several options.
- The programming means may also be configured to allow input, via the prescriber interface, of limits of variation of the measured clinical or therapeutic parameters. In one embodiment the dialysis machine comprises an alert means configured to issue an alert upon a deviation above or below a predefined limit of variation of a measured clinical or therapeutic parameter.
- In a further embodiment of the invention the patient interface comprises a display configured to display the at least one suggested treatment option. The display means being functionally linked to the re-evaluation means.
- In a further embodiment of the invention the patient interface and/or the prescriber interface is comprised by a graphical user interface. In one embodiment of the invention the graphical user interface is a touch screen.
- In a further embodiment of the invention the dialysis device comprises a prescriber interface and a programming means configured to allow, via the prescriber interface, input of a set of therapeutic objectives and a treatment plan and a condition-determining means that is configured to measure clinical or therapeutic parameters during an ongoing or resulting from a treatment session wherein the patient interface is configured to display the result of the treatment in relation to the set of therapeutic objectives as measured by means of the condition-determining means.
- In one embodiment of the invention, the patient is requested to respond to very specific clinical questions before modifying his treatment. Such responses may prevent the modification of said treatment. This set up may be referred to as a decision tree. The decision tree may also take into account information from recorded and/or measured parameters in order to better orient the patient and/or the treatment options as a function of the details gathered with the aid of these questions. The responses given by the patient will be communicated to the prescriber in the context of a medical monitoring of the patient after a reasonable time or, if appropriate, immediately, depending on the possible consequences on the state of health or therapeutic monitoring of the patient.
- According to a first aspect of the invention the dialysis device comprises an automated peritoneal dialysis machine also referred to as a cycler. According to a second aspect of the invention the dialysis device comprises a hemodialysis machine.
- The dialysis device according to the invention may be used advantageously in the context of home peritoneal dialysis and home hemodialysis respectively. In addition the dialysis device in the form of a hemodialysis machine may be used in a clinic or a self care setting.
- Below will be described the first and the second aspects of the invention, respectively, by way of illustrative examples.
- According to the first aspect of the invention where the dialysis device comprises an automated peritoneal dialysis machine, also referred to as a cycler, the dialysis treatment is performed by introducing dialysis fluid into the peritoneal cavity of a patient. The dialysis takes place over the peritoneum. After a period of time, typically 2 hours, the used dialysis fluid is drained from the peritoneal cavity and fresh dialysis fluid may be entered for continued treatment either directly or with a time delay. The dialysis fluid is usually available as a sterilized bagged fluid. For a treatment session during e.g. 8 hours multiple bags of fluid are used. The peritoneal dialysis machine in a cyclic manner assists in filling the peritoneum with fresh dialysis fluid from one bag at the time, possibly via a heater bag for heating the dialysis fluid to body temperature, and after a period of dwell draining the peritoneum and transferring the used dialysis fluid to a drain bag or to a drain.
- By means of the dialysis device according to the present invention it is possible to provide for an optimized use of the available fluids as a function of the duration of the treatment session.
- It is possible to reduce the duration of the dwell period in such a way as to ensure that the fluid from all bags is utilized during the available time for the treatment session while adhering to the intended number of fluid exchanges.
- According to one embodiment of the invention various treatment settings may be modified by the patient. In addition to the duration of a treatment session, it is also possible to modify the total volume of the dialysis fluid during a treatment session, the dialysis fluid composition or the number of exchange cycles, where one exchange cycle comprises filling, dwell and drain of dialysis fluid originating from one bag.
- In peritoneal dialysis, the therapeutic objectives to be reached over a period of n sessions may include one or more of the following: beta-2-microglobuline clearance, creatinine clearance, urea clearance, urea reduction ratio (URR), Kt/V ratio, sodium elimination, ultrafiltration volume, ultrafiltration rate, weight of the patient, blood chemistry parameters, haemoglobin and blood pressure. The blood chemistry parameters may include serum levels of phosphate, sodium, calcium, potassium, bicarbonate, albumin, urea or creatinine.
- The at least one suggested treatment option for a period of n consecutive treatment sessions is advantageously adapted to the parameters measured during the preceding m treatment sessions. Such parameters may be measured by the condition-determining means e.g. in the form of an ultrafiltration measurement means, a patient scale, blood samples or a means for analysis of effluent (drained dialysis fluid). The patient's glucose level may also be monitored during the treatment session by means of the condition-determining means. It is also possible to measure the glucose level in the drained dialysis fluid.
- According to one embodiment of the first aspect of the invention, the parameters measured during the preceding m treatment sessions include one or more of the following measurements: change in patient's weight, change in patient's blood pressure, change in patient's fat mass, quantity and nature of patient's food intake, quantity of water absorbed by patient, effective ultra-filtration, temperature of patient, physical strength of patient, residual renal function, urea removal, creatinine removal, change in blood parameters such as sodium, phosphate, calcium.
- The number n of consecutive peritoneal dialysis treatment sessions may be performed during a period lasting between 3 and 30 days, e.g. 7 days.
- The number m of preceding peritoneal dialysis treatment sessions may have been performed during a period lasting between 3 and 30 days, e.g. 7 days.
- According to one embodiment of the invention, a compensation of a treatment result is achieved by requiring the patient, for a consecutive treatment session, to correct the effects of the preceding sessions, limiting the freedom of modification. In this case, the patient is preferably forced to choose from at least one of the following constraints: minimum duration of treatment, modification of the dialysis fluid composition or combination of dialysis fluid compositions, modification to the number of exchange cycles or to the exchange volume, modification of water intake between treatment sessions, addition of further exchange sessions during the day, or modification of the dialysis fluid composition used during these exchanges.
- In one embodiment of the invention medical personnel responsible for the treatment of the patient is informed automatically by an alert when a deviation above or below a predefined limit is detected in relation to the therapeutic objectives that have been defined for the patient. The information may be transferred to the medical personnel remotely, for example by telephone or by Internet link.
- In case of peritoneal dialysis a deviation of ±30% over a 24-hour period may be accepted, provided that the weekly objective of, for example, 7 litres of ultrafiltration and 70 litres of creatinine clearance is achieved. The Kt/V objective may be 2.3.
- The prescriber may take into account the filtration surface of the patient's membrane, its transport quality (high, medium or low), the residual renal function, and the body mass and clinical parameters such as weight, blood pressure and total body water when designing the treatment plan.
- The prescriber in cooperation with the dialysis device configured for performing peritoneal dialysis defines the rules forming basis for the treatment options suggested by the re-evaluation means.
- If the ultrafiltration falls below 700 ml on one day, a modification of the glucose or sodium concentration of the dialysis fluid and/or the addition of other colloidal osmotic pressure solutions during the treatment and/or the daily exchange or exchanges will be suggested as a treatment option by the re-evaluation means. Alternatively, if the estimated clearance, on account of the reduced duration of the exchanges from 12 hours to 8 hours one night, drops by more than 30%, increase the number of exchanges the following night or prolong the duration of the treatment session from 10 hours to 13 hours, or else add supplementary daytime exchange sessions.
- The patient may vary the duration of the treatment session from one day to another.
- As a function of the preceding sessions, the device may permit programming a duration of a treatment session of between 8 and 12 hours in normal time, or of between 10 and 14 hours if it registers a cumulative therapeutic deficit due to treatment sessions that are too short in the last few days, or of a minimum of 14 hours if this deficit is deemed to be too great, or may even propose a supplementary daytime treatment session. The other parameter on which the patient may act is the water/sodium intake and/or the ultrafiltration in case of weight gain. Such intake or ultrafiltration parameters may as well form part of a suggested treatment option.
- According to the second aspect of the invention where the dialysis device comprises a hemodialysis machine the treatment may be carried out e.g. in a clinic where the patient is assisted by e.g. by a nurse, in a self care setting or at a patient's home. As disclosed above, the treatment of a patient with renal insufficiency is carried out according to a treatment plan created by a prescriber.
- The therapeutic objectives for a hemodialysis treatment typically include dialysis dose per unit of time, the patients so called “dry weight” and target ranges for various blood parameters. The “dry weight” is the weight at which the patient should be at the end of the treatment, that is, after fluid removal. Blood parameters of importance may be blood pressure, hematocrit, serum phosphate, serum potassium, serum sodium etc. For each parameter, a target range is specified. The dialysis dose may be specified for each treatment, e.g. as URR (Urea Reduction Ratio) or spKt/V (Single Pool Kt/V) or similar, or for a longer time, e.g. weekly stdKt/V (Weekly Standard Kt/V).
- The treatment schedule may be specified as one treatment session thrice weekly for a fixed period of time, typically 3-5 hours. Alternatively a treatment session may be scheduled every other day (i.e. 3.5 times per week), daily (i.e. 5-6 times per week, typically 2 hours) or during the night while sleeping, often referred to as nocturnal treatment (e.g. 3-6 times per week). The treatment schedule may be anything between these schedules, or a mix of two or more schedules, e.g. a mix of short daily and nocturnal treatments.
- Settings defining each treatment session comprises e.g. dialyzer type, dialysis fluid composition, dialysis fluid temperature, dialysis fluid flow rate, target blood flow and treatment duration. Typically also the targeted weight loss is entered for each treatment session. The targeted weight loss is based on how much the patient weighs before treatment and knowledge of the prescribed dry weight.
- In addition to prescribing a treatment schedule and settings for each treatment session, the prescriber may also set limits on allowed variation for each resulting setting. The limits are chosen by the prescriber to be safe for the patient, yet allow flexibility in how the individual dialysis treatment sessions are performed. For example, the prescriber may set a maximum allowed weight loss rate of 800 ml/min, to avoid hypotension which is a potentially dangerous condition.
- Below are disclosed two exemplary treatment plans. In the exemplary treatment plans the target blood parameters and the dialysis fluid composition have been left out for simplicity. However, the parameters disclosed serves to illustrate the second aspect of the invention.
- Treatment of patient A (daily dialysis e.g. performed in a home hemodialysis setting):
-
- Therapeutic objectives
- Dialysis dose: weekly stdKt/V=3.0
- Dry weight: 85 kg
- Treatment plan
- Treatment schedule
- 6 times per week: Monday-Saturday
- Treatment session settings
- Dialyzer: Polyflux 170H
- Fluid flow: 500 ml/min
- Blood flow 350 ml/min
- Duration: 2.5 hours
- Treatment schedule
- Therapeutic objectives
- Treatment of patient B (thrice weekly dialysis e.g. performed as in-center hemodialysis, either self-care or assisted):
-
- Therapeutic objectives
- Dialysis dose: spKt/V=1.2
- Dry weight: 72 kg
- Treatment plan
- Treatment schedule
- 3 times per week: Monday, Wednesday, Friday
- Treatment session settings
- Dialyzer: Polyflux 140H
- Fluid flow: 500 ml/min
- Blood flow 350 ml/min
- Duration: 5 hours
- Treatment schedule
- Therapeutic objectives
- The data representing the therapeutic objectives, the treatment plan (including schedule of treatments and session settings) and variation limits are entered into a programming means of the hemodialysis machine, via a prescriber interface. The prescriber interface may form part of the hemodialysis machine itself. Alternatively, the dialysis device comprises several parts such that the prescriber interface is separate from the dialysis machine itself.
- One embodiment of the second aspect of the invention is related to home hemodialysis where the patient treats himself at a home setting, possibly assisted by e.g. a family member. A home dialysis device comprises two separate components; a computer system at the clinic and the hemodialysis machine in the patient's home. The computer system at the clinic comprises the prescriber interface, where the prescriber enters the treatment plan. The treatment plan may be electronically transferred to the hemodialysis machine, e.g. via a portable electronic media such as a USB memory or via a direct electronic connection by telephone line or internet. Once the treatment plan is transferred to the hemodialysis machine the treatment may commence without further changes.
- One embodiment of the second aspect of the invention is related to dialysis treatment performed in an in-center setting where the patient is assisted by a physician or a nurse. In the in-center clinic, each hemodialysis machine will serve several patients. The dialysis device for the in-center setting may comprise a single computer system for the whole clinic and several hemodialysis machines. The treatment plan for each patient is stored on the computer system until the patient to be treated has been assigned to a specific hemodialysis machine. The therapeutic objectives and/or the treatment plan may be transferred to the hemodialysis machine via an electronic network. Alternatively the therapeutic objectives and the treatment plan may be transferred to the hemodialysis machine from a personal portable memory device, such as a USB memory or an electronic patient card. Once the therapeutic objectives and/or the treatment plan is transferred to the hemodialysis machine the re-evaluation means will suggest at least one treatment option and the treatment may commence without further changes once one of these options is selected via the patient interface.
- According to one embodiment of the second aspect of the invention the patient interface allows for modifications of any of the resulting treatment settings. Reasonable modifications to the settings is allowed to be made via the patient interface, i.e. modifications are allowed as long as they are within limits set by the prescriber e.g. the duration of a treatment session may be set between 3 and 7 hours and it will not be possible to enter a duration of treatment session outside these limits.
- Patient B according to the above exemplified treatment plan, may want to shorten the duration of the treatment session from 5 to 4 hours on a particular day. If this new duration of treatment is within the set limits the modification is allowed.
- Based on a modified setting the re-evaluation means determines how other treatment settings may be changed to achieve the therapeutic objectives and suggests at least one treatment option. The re-evaluation means may also take into account other available data of the patient such as the treatment history and current treatment parameters when suggesting new treatment options to achieve the therapeutic objectives.
- Patient A according to the above exemplified treatment plan, has gained 3.0 kg since the last treatment session, a weight which has to be taken off to reach the therapeutic objective of the dry weight. The maximum allowed weight loss rate may have been set to 800 g/hour, in which case the maximum total weight loss that may be achieved in the prescribed 2.5 hour treatment is 2.0 kg. The re-evaluation means suggests a treatment option where the duration of the treatment is prolonged to 3 hours and 45 minutes, which allows the dry weight to be reached while maintaining a safe weight removal rate. The re-evaluation means may suggest a second treatment option, where a weight loss of only 2.0 kg in the current treatment session is reached, leaving a “debt” until the next treatment session.
- During a treatment of Patient B, the maximum blood flow that may be achieved is 300 ml/min due to that the needles have been somewhat misplaced during cannulation. This is lower than the blood flow of 350 ml/min according to the entered treatment plan. Thus, the treatment dose (spKt/V=1.2) will not be reached as planned. The re-evaluation means suggests a treatment option showing an increase of the dialysis fluid flow rate from 500 to 800 ml/min. If increase of dialysis fluid flow is not sufficient to reach the treatment dose objective, additionally the re-evaluation means will suggest a treatment option where the treatment time is extended. Alternatively, the re-evaluation means may suggest a treatment option resulting in that a dose “debt” is left for the next treatment session or treatment sessions.
- As exemplified above, there may be one or several options for the patient to choose from to reach the therapeutic objective.
- In one embodiment of the invention the patient interface displays a list including at least one setting that may be modified.
- If Patient B in the example above decides that an extension of treatment time of 15 minutes is acceptable, then he/she sets the treatment time to be 5 hours and 15 minutes—and the re-evaluation means dynamically shows how high the dialysis fluid flow has to be to reach the treatment dose target. Once the user has decided that the suggested combination of parameters are acceptable, they are accepted via the patient interface and the hemodialysis machine dynamically makes the necessary adjustments.
- In an alternative embodiment of the second aspect of the invention the hemodialysis machine comprises a condition-measuring means providing data so as to determine how well the therapeutic objectives are reached. Some therapeutic objectives are possible to measure or estimate e.g. the dialysis dose, which may be measured using blood samples analyzed for BUN (Blood Urea Nitrogen), or estimated using on-line clearance estimating technology. Thus, the re-evaluation means may take into account measurements conducted by the condition-measuring means when suggesting treatment options to achieve the therapeutic objective of the treatment dose. Parameters such as plasma phosphate content may be evaluated by means of blood samples in order to follow up how well therapeutic objectives on such parameters are achieved. Results of blood sample analysis is preferably entered into a treatment history record whereby the re-evaluation means may be configured to use the patient history data for suggesting consecutive treatment options.
- In an alternative embodiment of the second aspect of the invention, the re-evaluation means takes into account the treatment history as well as several future treatment sessions when suggesting a treatment option, as will be described below. In addition to the treatment plan, this requires storing treatment history of each patient. In the home hemodialysis setting the treatment history may be stored in the memory comprised by the control system of the hemodialysis machine, since it is being used by a single patient. In the case of in-center dialysis, the treatment history of each patient has to be stored either on the clinic computer system (e.g. via network) or on a personal portable memory device. The data representing the patient history would typically include data related to previous treatment sessions (time and date, duration, blood flow or blood volume processed, fluid flow, dialysis fluid composition, weight loss, achieved online clearance etc) and possibly also indicators of therapeutic objectives (achieved dialysis dose, pre-dialysis weight, blood parameters such as pressure, haemoglobin, etc). The patient history to be taken into account typically comprises the treatment sessions during 7 preceding days.
- If Patient A has a weight loss “debt” from an earlier treatment session, as suggested in the example above, the re-evaluation means would suggest a treatment option having longer treatment duration. If the weight loss debt is significant, the re-evaluation means may suggest a treatment option where the weight is removed over several future treatment sessions.
- If patient A has one or more treatment sessions with clearance efficiency below what is expected by the prescriber (e.g. due to reduced blood flow or reduced time), the re-evaluation means will suggest a treatment option at start of the next treatment session to achieve the targeted weekly dose of stdKt/V=3.0. This treatment option may comprise increasing dialysis fluid flow, increasing blood flow, increasing time or choosing a different dialyzer with a larger membrane surface area.
- If Patient A knows that he will have limited time for treatment tomorrow, he may choose to increase duration of the treatment session today, for example from 2.5 hours to 3.5 hours. This will increase the dialysis dose today and thus put him/her ahead of schedule in achieving the weekly dose target. The re-evaluation means will then suggest a shorter time for the treatment tomorrow.
- Examples VI and VII indicate that the patient may be below as well as above a therapeutic objective, in these examples the weekly dialysis dose target. The patient interface according to the invention therefore includes an indicator that in a simple and understandable fashion shows how well the therapeutic objectives are reached. This may be in the shape of a percentage figure, e.g. 85%, or a graphical representation such as a bar graph. The achievement of therapeutic objectives may also be shown over time, e.g. by a diagram with time on the horizontal axis. For example, if the therapeutic objective is the weekly dialysis dose, the graph may display the target as a horizontal line, and the actually achieved dose may be represented as connected points, where each point represents the achieved weekly dose over the last 7 days.
- As stated above the dialysis device may comprise a condition-determining means configured to measure parameters relevant for the therapeutic objective. The condition-determining means may comprise e.g. an online clearance estimating device, a blood pressure monitor, a blood composition analyser, a patient scale. The condition-determining means may be configured to detect failure to meet the therapeutic objectives and to issue an alert to the patient (via the patient interface) and/or to the prescriber via e.g. telephone line or internet connection.
- All of the steps, as well as any sub-sequence of steps, described above (comprising the first as well as the second aspect thereof) may be controlled by means of a programmed computer apparatus forming part of the dialysis device. Moreover, although the embodiments of the invention described above comprise computer apparatus and processes performed in computer apparatus, the invention thus also extends to computer programs, particularly computer programs on or in a carrier, adapted for putting the invention into practice. The program may be in the form of source code, object code, a code intermediate source and object code such as in partially compiled form, or in any other form suitable for use in the implementation of the procedure according to the invention. The program may either be a part of an operating system, or be a separate application. The carrier may be any entity or device capable of carrying the program. For example, the carrier may comprise a storage medium, such as a Flash memory, a ROM (Read Only Memory), for example a DVD (Digital Video/Versatile Disk), a CD (Compact Disc), an EPROM (Erasable Programmable Read-Only Memory), an EEPROM (Electrically Erasable Programmable Read-Only Memory), or a magnetic recording medium, for example a floppy disc or a hard disc. Further, the carrier may be a transmissible carrier such as an electrical or optical signal which may be conveyed via electrical or optical cable or by radio or by other means. When the program is embodied in a signal which may be conveyed directly by a cable or other device or means, the carrier may be constituted by such cable or device or means. Alternatively, the carrier may be an integrated circuit in which the program is embedded, the integrated circuit being adapted for performing, or for use in the performance of, the relevant procedures.
- The term “comprises/comprising” when used in this specification is taken to specify the presence of stated features, integers, steps or components. However, the term does not preclude the presence or addition of one or more additional features, integers, steps or components or groups thereof.
- The reference to prior art in this specification is not, and should not be taken as, an acknowledgment or any suggestion that the referenced prior art forms part of the common general knowledge in Australia, or in any other country.
Claims (25)
1.-54. (canceled)
55. A dialysis device receiving, via a prescriber interface, data representing a set of therapeutic objectives and a treatment plan, which comprises a treatment schedule for a number of consecutive treatment sessions and a set of settings of a treatment session, the dialysis device comprising:
a patient interface, and
a computer system receiving input data, indicative of a modified setting, via the patient interface, wherein the computer system:
modifies at least one of the settings of the set of settings based on the input data received via the patient interface, and
re-evaluates the treatment plan as a function of the at least one modified setting to generate a suggestion including at least one treatment option comprising a suggested set of settings of a treatment session to achieve said set of therapeutic objectives.
56. The dialysis device according to claim 55 , wherein the computer system further causes the dialysis device to measure clinical or therapeutic parameters during a treatment session using the dialysis system, wherein the suggestion of the at least one treatment option generated during the re-evaluation step is based on a function of the measured parameters.
57. The dialysis device according to claim 56 , wherein the treatment session includes at least one preceding treatment session.
58. The dialysis device according to claim 56 or 57 , wherein the suggestion of the at least one treatment option generated during the re-evaluation step is generated based on the at least one modified setting and the at least one measured parameter.
59. The dialysis device according to claim 56 , wherein the suggestion of the at least one treatment option generated during the re-evaluation step is generated based on a function of the measured parameters during an on-going treatment session and of the measured parameters of at least one preceding treatment session.
60. The dialysis device according to claim 55 , wherein the suggestion of the at least one treatment option generated during the re-evaluation step is presented on the patient interface, and the computer system receives a selection inputted via the patient interface of one of the treatment options, whereby the computer system in response to the selection adjusts the settings as a consequence of the selection to carry out the treatment session in accordance with the selected treatment option.
61. The dialysis device according to claim 55 , wherein the computer system receives data via the prescriber interface of limits of variation of the at least one setting and the computer system limits the modification of each setting to be within the limits.
62. The dialysis device according to claim 56 , wherein the received data via the prescriber interface includes limits of variation of the measured clinical or therapeutic parameters.
63. The dialysis device according to claim 62 , comprising an alert configured to issue an alert upon a deviation above or below a predefined limit of variation.
64. The dialysis device according to claim 55 , wherein the therapeutical objective is set to be reached over a period of a number of treatment sessions, and wherein the re-evaluation step is configured to take into account a treatment history and several future treatment sessions when suggesting said at least one treatment option, to secure that the treatment objective is reached while allowing flexibility in the individual treatment sessions.
65. The dialysis device according to claim 55 , wherein said at least one of said settings is modified via the patient interface during an on-going treatment session, and wherein the re-evaluation step, as a consequence of the modification, generates a suggestion of at least one treatment option at one or more consecutive treatment sessions.
66. The dialysis device according to claim 55 , which comprises a hemodialysis machine.
67. A computer program product comprising computer code which, when executed on a data-processing system, is adapted to carry out a method of operating a dialysis device, said dialysis device comprising a computer system and a patient interface, the method comprising:
receiving a set of therapeutic objectives and a treatment plan, which comprises a treatment schedule for a number of consecutive treatment sessions and a set of settings of a treatment session, wherein the dialysis device is adapted to execute the treatment plan;
receiving via a patient interface a modification to at least one of the settings of the set of settings of the treatment session;
re-evaluating the treatment plan based on the received modification of at least one of said settings, wherein the re-evaluation includes generation of a suggestion of at least one treatment option determined based on the modification of at least one setting, the set of therapeutic objectives and the treatment plan, wherein the at least one treatment option comprising a suggested set of settings of a treatment session to achieve said set of therapeutic objectives.
68. The computer program product according to claim 67 , wherein the method further comprises measuring clinical or therapeutic parameters during a treatment session and the re-evaluation step determines the at least one treatment option as a function of the measured parameters.
69. The computer program product according to claim 68 , wherein the clinical or therapeutic parameters are measured during at least one preceding treatment session.
70. The computer program product according to claim 68 or 69 , wherein the at least one treatment option suggested in the re-evaluation step is a function of the at least one modified setting and the measured parameters.
71. The computer program product according to claim 68 , wherein the re-evaluation step determines the at least one treatment option as a function of the measured parameters of an on-going treatment session and of at least one preceding treatment session.
72. The computer program product according to claim 67 , wherein the re-evaluation step suggests treatment options, and the method further comprises receiving an input from the patient interface indicating a selection of one of the suggested treatment options and adjusting the settings in response to the selection to carry out the treatment session in accordance with the selected treatment option.
73. The computer program product according to claim 67 , further comprising receiving data indicating limits of variation of each of the at least one setting that are allowed to be modified via the patient interface, thereby allowing modification of each setting within these limits.
74. The computer program product according to claim 68 , further comprising receiving data indicating limits of variation of the measured clinical or therapeutic parameters.
75. A dialysis device receiving data representing a set of therapeutic objectives and a prescribed treatment plan, wherein the prescribed treatment plan includes a treatment schedule for consecutive treatment sessions and a set of settings to the dialysis device for the treatment sessions, the dialysis device comprising:
a patient interface, and
a computer system receiving input data from the patient interface and storing the input data and the received set of therapeutic objectives and the received prescribed treatment plan in a memory, wherein the computer system executes a computer code stored in the memory to:
modify at least one of the settings of the set of settings based on the input data received from the patient interface, and
in response to the modification of said at least one of the settings, re-evaluate the prescribed treatment plan and generate at least one suggested treatment option for achieving the set of therapeutic objectives, wherein each of the at least one suggested treatment option includes a set of settings to the dialysis device for one or more of the consecutive treatment sessions.
76. The dialysis device of claim 75 wherein the re-evaluation of the treatment plan includes adjusting at least one of the other of the settings of the set of settings in the treatment plan.
77. A computer program product comprising computer code which, when executed on a data-processing system of a dialysis device, is adapted to carry out a method of operating the dialysis device, the method comprising:
receiving by the dialysis device a set of therapeutic objectives and a treatment plan, which comprises a treatment schedule for consecutive treatment sessions and a set of settings of the dialysis device for the treatment sessions;
receiving from a patient interface for the dialysis device a modification to at least one of the settings of the set of settings of the treatment session;
re-evaluating the treatment plan based on the received modification of the at least one of said settings, wherein the re-evaluation includes generating a suggestion of at least one treatment option, wherein the treatment option is determined based on the modification of the at least one setting, the set of therapeutic objectives and the treatment plan, and wherein the at least one treatment option comprises a suggested set of settings of a treatment session to achieve said set of therapeutic objectives.
78. The computer program of claim 76 wherein the re-evaluation of the treatment plan includes adjusting at least one of the other of the settings of the set of settings in the treatment plan.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IBPCT/IB2009/051225 | 2009-03-24 | ||
IB2009051225 | 2009-03-24 | ||
PCT/EP2010/053837 WO2010108955A1 (en) | 2009-03-24 | 2010-03-24 | Dialysis device |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2010/053837 A-371-Of-International WO2010108955A1 (en) | 2009-03-24 | 2010-03-24 | Dialysis device |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/872,977 Continuation US10722634B2 (en) | 2009-03-24 | 2018-01-16 | Dialysis device |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120029937A1 true US20120029937A1 (en) | 2012-02-02 |
Family
ID=42295430
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/260,456 Abandoned US20120029937A1 (en) | 2009-03-24 | 2010-03-24 | Dialysis device |
US15/872,977 Active 2031-04-08 US10722634B2 (en) | 2009-03-24 | 2018-01-16 | Dialysis device |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/872,977 Active 2031-04-08 US10722634B2 (en) | 2009-03-24 | 2018-01-16 | Dialysis device |
Country Status (5)
Country | Link |
---|---|
US (2) | US20120029937A1 (en) |
EP (2) | EP2957305B1 (en) |
CN (1) | CN102361657B (en) |
ES (1) | ES2548570T3 (en) |
WO (1) | WO2010108955A1 (en) |
Cited By (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100140149A1 (en) * | 2008-10-30 | 2010-06-10 | Barry Neil Fulkerson | Modular, Portable Dialysis System |
US20100234786A1 (en) * | 2009-02-12 | 2010-09-16 | Barry Neil Fulkerson | System and Method for Detection of Disconnection in an Extracorporeal Blood Circuit |
US20100252490A1 (en) * | 2008-09-12 | 2010-10-07 | Fulkerson Barry N | Modular Reservoir Assembly for a Hemodialysis and Hemofiltration System |
US20110087499A1 (en) * | 2009-10-13 | 2011-04-14 | Nxstage Medical, Inc. | Dialysis treatment planning and cost optimization |
US20120071815A1 (en) * | 2010-09-17 | 2012-03-22 | Baxter Healthcare S.A. | Drain and fill logic for automated peritoneal dialysis |
US20130006171A1 (en) * | 2011-06-29 | 2013-01-03 | Fresenius Medical Care Deutschland Gmbh | Dialysis machine |
US20130056418A1 (en) * | 2011-09-01 | 2013-03-07 | Fresenius Medical Care Deutschland Gmbh | Dialysate flow control |
US8395761B2 (en) | 2007-10-11 | 2013-03-12 | Fresenius Medical Care Holdings, Inc. | Thermal flow meter |
US20130310726A1 (en) * | 2012-05-15 | 2013-11-21 | Baxter Healthcare S.A. | Home Medical Device Systems and Methods for Therapy Prescription and Tracking, Servicing and Inventory |
US8597505B2 (en) | 2007-09-13 | 2013-12-03 | Fresenius Medical Care Holdings, Inc. | Portable dialysis machine |
US8771511B2 (en) | 2007-11-29 | 2014-07-08 | Fresenius Medical Care Holdings, Inc. | Disposable apparatus and kit for conducting dialysis |
US9157786B2 (en) | 2012-12-24 | 2015-10-13 | Fresenius Medical Care Holdings, Inc. | Load suspension and weighing system for a dialysis machine reservoir |
WO2015154859A1 (en) * | 2014-04-08 | 2015-10-15 | Fresenius Medical Care Deutschland Gmbh | Method for estimating the duration of a peritoneal dialysis treatment |
US9295772B2 (en) | 2007-11-29 | 2016-03-29 | Fresenius Medical Care Holdings, Inc. | Priming system and method for dialysis systems |
US9308307B2 (en) | 2007-09-13 | 2016-04-12 | Fresenius Medical Care Holdings, Inc. | Manifold diaphragms |
US9328969B2 (en) | 2011-10-07 | 2016-05-03 | Outset Medical, Inc. | Heat exchange fluid purification for dialysis system |
US9354640B2 (en) | 2013-11-11 | 2016-05-31 | Fresenius Medical Care Holdings, Inc. | Smart actuator for valve |
US9352282B2 (en) | 2007-09-25 | 2016-05-31 | Fresenius Medical Care Holdings, Inc. | Manifolds for use in conducting dialysis |
US9360129B2 (en) | 2009-01-12 | 2016-06-07 | Fresenius Medical Care Holdings, Inc. | Valve system |
US9358331B2 (en) | 2007-09-13 | 2016-06-07 | Fresenius Medical Care Holdings, Inc. | Portable dialysis machine with improved reservoir heating system |
US9402945B2 (en) | 2014-04-29 | 2016-08-02 | Outset Medical, Inc. | Dialysis system and methods |
US9545469B2 (en) | 2009-12-05 | 2017-01-17 | Outset Medical, Inc. | Dialysis system with ultrafiltration control |
US9582164B2 (en) | 2012-08-31 | 2017-02-28 | Gambro Lundia Ab | Dialysis apparatus with versatile user interface and method and computer program therefor |
EP2892584B1 (en) * | 2012-09-04 | 2017-06-14 | Fresenius Medical Care Deutschland GmbH | Blood treatment apparatus with a device for quantifying and displaying a time buffer of a patient |
US9861733B2 (en) | 2012-03-23 | 2018-01-09 | Nxstage Medical Inc. | Peritoneal dialysis systems, devices, and methods |
EP3281655A1 (en) * | 2016-08-10 | 2018-02-14 | Medtronic Inc. | Intersession adaptive peritoneal dialysis fluid removal for multiple session optimization |
US9907897B2 (en) | 2011-03-23 | 2018-03-06 | Nxstage Medical, Inc. | Peritoneal dialysis systems, devices, and methods |
US20180162230A1 (en) * | 2016-12-09 | 2018-06-14 | Mitsubishi Jidosha Kogyo Kabushiki Kaisha | Power source control device and power source control method |
US20180311428A1 (en) * | 2015-10-20 | 2018-11-01 | Fresenius Medical Care Deutschland Gmbh | Blood treatment device and method of preparing a prescription |
US10589014B2 (en) | 2016-12-21 | 2020-03-17 | Baxter International Inc. | Medical fluid delivery system including remote machine updating and control |
US20200155748A1 (en) * | 2018-11-16 | 2020-05-21 | Medtronic, Inc. | Peritoneal dialysis adequacy meaurements |
US20200179583A1 (en) * | 2018-12-10 | 2020-06-11 | Medtronic, Inc. | Precision peritoneal dialysis therapy based on dialysis adequacy meaurements |
US10744253B2 (en) | 2016-08-10 | 2020-08-18 | Medtronic, Inc. | Adaptive peritoneal dialysis intra-session adjustments for overall session optimization |
US10758659B2 (en) | 2016-08-10 | 2020-09-01 | Medtronic, Inc. | Peritoneal dialysis filtrate sampling and adaptive prescription |
US10874790B2 (en) | 2016-08-10 | 2020-12-29 | Medtronic, Inc. | Peritoneal dialysis intracycle osmotic agent adjustment |
US10967112B2 (en) | 2011-04-29 | 2021-04-06 | Medtronic, Inc. | Adaptive system for blood fluid removal |
US10994064B2 (en) | 2016-08-10 | 2021-05-04 | Medtronic, Inc. | Peritoneal dialysate flow path sensing |
US11013843B2 (en) | 2016-09-09 | 2021-05-25 | Medtronic, Inc. | Peritoneal dialysis fluid testing system |
US11058512B2 (en) * | 2015-12-21 | 2021-07-13 | Fresenius Medical Care Deutschland Gmbh | Sensor-controlled display output for dialysis machines |
US11207454B2 (en) | 2018-02-28 | 2021-12-28 | Nxstage Medical, Inc. | Fluid preparation and treatment devices methods and systems |
US11393565B2 (en) | 2016-12-21 | 2022-07-19 | Baxter International Inc. | Medical fluid delivery system including a mobile platform for patient engagement and treatment compliance |
US11420014B2 (en) | 2015-07-20 | 2022-08-23 | Roivios Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
US11471583B2 (en) * | 2015-07-20 | 2022-10-18 | Roivios Limited | Method of removing excess fluid from a patient with hemodilution |
US11525798B2 (en) | 2012-12-21 | 2022-12-13 | Fresenius Medical Care Holdings, Inc. | Method and system of monitoring electrolyte levels and composition using capacitance or induction |
US11534537B2 (en) | 2016-08-19 | 2022-12-27 | Outset Medical, Inc. | Peritoneal dialysis system and methods |
US11541205B2 (en) | 2015-07-20 | 2023-01-03 | Roivios Limited | Coated urinary catheter or ureteral stent and method |
US11612714B2 (en) | 2015-07-20 | 2023-03-28 | Roivios Limited | Systems and methods for inducing negative pressure in a portion of a urinary tract of a patient |
US11724013B2 (en) | 2010-06-07 | 2023-08-15 | Outset Medical, Inc. | Fluid purification system |
US11752300B2 (en) | 2015-07-20 | 2023-09-12 | Roivios Limited | Catheter device and method for inducing negative pressure in a patient's bladder |
US11850344B2 (en) | 2021-08-11 | 2023-12-26 | Mozarc Medical Us Llc | Gas bubble sensor |
US11896785B2 (en) | 2015-07-20 | 2024-02-13 | Roivios Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
US11918754B2 (en) | 2015-07-20 | 2024-03-05 | Roivios Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
US11955234B2 (en) * | 2016-06-30 | 2024-04-09 | Gambro Lundia Ab | Extracorporeal blood treatment system and method including modifiable settings |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2811544C (en) | 2010-09-20 | 2020-01-07 | Gambro Lundia Ab | Obtaining control settings for a dialysis machine |
DE102011121668A1 (en) * | 2011-12-20 | 2013-06-20 | Fresenius Medical Care Deutschland Gmbh | Method and device for preparing medical treatment devices |
EP2883557B1 (en) * | 2013-12-10 | 2017-05-24 | Gambro Lundia | Extracorporeal blood treatment system for individualized treatment. |
CN104174084A (en) * | 2014-09-15 | 2014-12-03 | 昆山韦睿医疗科技有限公司 | Peritoneal dialysis equipment and operation method thereof |
DE102014013886A1 (en) * | 2014-09-18 | 2016-03-24 | Fresenius Medical Care Deutschland Gmbh | Method and device for predicting one or more parameters characteristic of the outcome of a blood treatment |
DE102014113462A1 (en) * | 2014-09-18 | 2016-03-24 | Fresenius Medical Care Deutschland Gmbh | Method and apparatus for accounting for patient feedback in blood treatment |
DE102014013603A1 (en) * | 2014-09-18 | 2016-03-24 | Fresenius Medical Care Deutschland Gmbh | Method and device for controlling the duration of treatment of medical device treatments |
AU2015331993B2 (en) | 2014-10-17 | 2020-07-09 | Debiotech S.A. | Delivery system and mode of operation thereof |
EP3018601B1 (en) | 2014-11-10 | 2021-06-23 | B. Braun Avitum AG | Blood purification device graphical user interface method |
WO2016087897A1 (en) * | 2014-12-04 | 2016-06-09 | Debiotech S.A. | User interface for dialysis treatment |
EP3548112A1 (en) * | 2016-11-29 | 2019-10-09 | Gambro Lundia AB | Patient and treatment records |
CN112689525A (en) | 2018-08-21 | 2021-04-20 | 美敦力瓦斯科尔勒公司 | Guide extension catheter assembly, system and method of use |
CN108986419B (en) * | 2018-10-17 | 2021-02-26 | 暨南大学 | Data alarming method for hemodialysis |
EP4054670A2 (en) * | 2019-11-05 | 2022-09-14 | Baxter International Inc. | Medical fluid delivery system including analytics for managing patient engagement and treatment compliance |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070175827A1 (en) * | 2006-02-02 | 2007-08-02 | Cardiac Pacemakers, Inc. | Cardiac rhythm management device and sensor-suite for the optimal control of ultrafiltration and renal replacement therapies |
US20080033402A1 (en) * | 2006-08-03 | 2008-02-07 | Blomquist Michael L | Interface for medical infusion pump |
US7988849B2 (en) * | 2008-06-03 | 2011-08-02 | Baxter International Inc. | Customizable personal dialysis device having ease of use and therapy enhancement features |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5326476A (en) | 1991-04-19 | 1994-07-05 | Althin Medical, Inc. | Method and apparatus for kidney dialysis using machine with programmable memory |
IT1255260B (en) * | 1991-07-16 | 1995-10-20 | Hospal Dasco Spa | METHOD OF SURVEILLANCE OF A THERAPY IN A DIALYTIC TREATMENT. |
US5788851A (en) | 1995-02-13 | 1998-08-04 | Aksys, Ltd. | User interface and method for control of medical instruments, such as dialysis machines |
EP1396274B2 (en) * | 2002-09-05 | 2013-05-22 | Gambro Lundia AB | Controller for a blood treatment equipment |
US20060195064A1 (en) * | 2005-02-28 | 2006-08-31 | Fresenius Medical Care Holdings, Inc. | Portable apparatus for peritoneal dialysis therapy |
DE502005006461D1 (en) * | 2005-03-05 | 2009-03-05 | Braun B Avitum Ag | Dialysis machine with a device for determining the dialysis dose |
JP4822258B2 (en) * | 2005-11-11 | 2011-11-24 | 日機装株式会社 | Hemodialysis machine |
DE102006032926A1 (en) * | 2006-07-15 | 2008-01-17 | Fresenius Medical Care Deutschland Gmbh | Method and device for prescribing treatment parameters for extracorporeal dialysis treatments |
US8168063B2 (en) * | 2008-07-09 | 2012-05-01 | Baxter International Inc. | Dialysis system having filtering method for determining therapy prescriptions |
-
2010
- 2010-03-24 ES ES10710329.3T patent/ES2548570T3/en active Active
- 2010-03-24 EP EP15177324.9A patent/EP2957305B1/en active Active
- 2010-03-24 WO PCT/EP2010/053837 patent/WO2010108955A1/en active Application Filing
- 2010-03-24 EP EP10710329.3A patent/EP2411069B1/en active Active
- 2010-03-24 CN CN201080013027.4A patent/CN102361657B/en active Active
- 2010-03-24 US US13/260,456 patent/US20120029937A1/en not_active Abandoned
-
2018
- 2018-01-16 US US15/872,977 patent/US10722634B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070175827A1 (en) * | 2006-02-02 | 2007-08-02 | Cardiac Pacemakers, Inc. | Cardiac rhythm management device and sensor-suite for the optimal control of ultrafiltration and renal replacement therapies |
US20080033402A1 (en) * | 2006-08-03 | 2008-02-07 | Blomquist Michael L | Interface for medical infusion pump |
US7988849B2 (en) * | 2008-06-03 | 2011-08-02 | Baxter International Inc. | Customizable personal dialysis device having ease of use and therapy enhancement features |
Cited By (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8597505B2 (en) | 2007-09-13 | 2013-12-03 | Fresenius Medical Care Holdings, Inc. | Portable dialysis machine |
US10383993B2 (en) | 2007-09-13 | 2019-08-20 | Fresenius Medical Care Holdings, Inc. | Pump shoe for use in a pumping system of a dialysis machine |
US9358331B2 (en) | 2007-09-13 | 2016-06-07 | Fresenius Medical Care Holdings, Inc. | Portable dialysis machine with improved reservoir heating system |
US9308307B2 (en) | 2007-09-13 | 2016-04-12 | Fresenius Medical Care Holdings, Inc. | Manifold diaphragms |
US9517296B2 (en) | 2007-09-13 | 2016-12-13 | Fresenius Medical Care Holdings, Inc. | Portable dialysis machine |
US10258731B2 (en) | 2007-09-13 | 2019-04-16 | Fresenius Medical Care Holdings, Inc. | Manifold diaphragms |
US11071811B2 (en) | 2007-09-13 | 2021-07-27 | Fresenius Medical Care Holdings, Inc. | Portable dialysis machine |
US11318248B2 (en) | 2007-09-13 | 2022-05-03 | Fresenius Medical Care Holdings, Inc. | Methods for heating a reservoir unit in a dialysis system |
US10857281B2 (en) | 2007-09-13 | 2020-12-08 | Fresenius Medical Care Holdings, Inc. | Disposable kits adapted for use in a dialysis machine |
US10596310B2 (en) | 2007-09-13 | 2020-03-24 | Fresenius Medical Care Holdings, Inc. | Portable dialysis machine |
US11224841B2 (en) | 2007-09-25 | 2022-01-18 | Fresenius Medical Care Holdings, Inc. | Integrated disposable component system for use in dialysis systems |
US10022673B2 (en) | 2007-09-25 | 2018-07-17 | Fresenius Medical Care Holdings, Inc. | Manifolds for use in conducting dialysis |
US9352282B2 (en) | 2007-09-25 | 2016-05-31 | Fresenius Medical Care Holdings, Inc. | Manifolds for use in conducting dialysis |
US8395761B2 (en) | 2007-10-11 | 2013-03-12 | Fresenius Medical Care Holdings, Inc. | Thermal flow meter |
US10034973B2 (en) | 2007-11-29 | 2018-07-31 | Fresenius Medical Care Holdings, Inc. | Disposable apparatus and kit for conducting dialysis |
US10758661B2 (en) | 2007-11-29 | 2020-09-01 | Fresenius Medical Care Holdings, Inc. | Disposable apparatus and kit for conducting dialysis |
US10758662B2 (en) | 2007-11-29 | 2020-09-01 | Fresenius Medical Care Holdings, Inc. | Priming system and method for dialysis systems |
US8771511B2 (en) | 2007-11-29 | 2014-07-08 | Fresenius Medical Care Holdings, Inc. | Disposable apparatus and kit for conducting dialysis |
US11439738B2 (en) | 2007-11-29 | 2022-09-13 | Fresenius Medical Care Holdings, Inc. | Methods and Systems for fluid balancing in a dialysis system |
US9295772B2 (en) | 2007-11-29 | 2016-03-29 | Fresenius Medical Care Holdings, Inc. | Priming system and method for dialysis systems |
US9415152B2 (en) | 2007-11-29 | 2016-08-16 | Fresenius Medical Care Holdings, Inc. | Disposable apparatus and kit for conducting dialysis |
US10095840B2 (en) * | 2008-07-09 | 2018-10-09 | Baxter International Inc. | System and method for performing renal therapy at a home or dwelling of a patient |
US10061899B2 (en) * | 2008-07-09 | 2018-08-28 | Baxter International Inc. | Home therapy machine |
US10068061B2 (en) * | 2008-07-09 | 2018-09-04 | Baxter International Inc. | Home therapy entry, modification, and reporting system |
US20160217265A1 (en) * | 2008-07-09 | 2016-07-28 | Baxter International Inc. | Home therapy entry, modification, and reporting system |
US10224117B2 (en) * | 2008-07-09 | 2019-03-05 | Baxter International Inc. | Home therapy machine allowing patient device program selection |
US20160239637A1 (en) * | 2008-07-09 | 2016-08-18 | Baxter International Inc. | System and method for performing renal therapy at a home or dwelling of a patient |
US9759710B2 (en) | 2008-09-12 | 2017-09-12 | Fresenius Medical Care Holdings, Inc. | Modular reservoir assembly for a hemodialysis and hemofiltration system |
US9199022B2 (en) | 2008-09-12 | 2015-12-01 | Fresenius Medical Care Holdings, Inc. | Modular reservoir assembly for a hemodialysis and hemofiltration system |
US20100252490A1 (en) * | 2008-09-12 | 2010-10-07 | Fulkerson Barry N | Modular Reservoir Assembly for a Hemodialysis and Hemofiltration System |
US20100140149A1 (en) * | 2008-10-30 | 2010-06-10 | Barry Neil Fulkerson | Modular, Portable Dialysis System |
US10758868B2 (en) | 2008-10-30 | 2020-09-01 | Fresenius Medical Care Holdings, Inc. | Methods and systems for leak detection in a dialysis system |
US10670577B2 (en) | 2008-10-30 | 2020-06-02 | Fresenius Medical Care Holdings, Inc. | Modular reservoir assembly for a hemodialysis and hemofiltration system |
US10035103B2 (en) | 2008-10-30 | 2018-07-31 | Fresenius Medical Care Holdings, Inc. | Modular, portable dialysis system |
US11169137B2 (en) | 2008-10-30 | 2021-11-09 | Fresenius Medical Care Holdings, Inc. | Modular reservoir assembly for a hemodialysis and hemofiltration system |
US9360129B2 (en) | 2009-01-12 | 2016-06-07 | Fresenius Medical Care Holdings, Inc. | Valve system |
US10808861B2 (en) | 2009-01-12 | 2020-10-20 | Fresenius Medical Care Holdings, Inc. | Valve system |
US10197180B2 (en) | 2009-01-12 | 2019-02-05 | Fresenius Medical Care Holdings, Inc. | Valve system |
US20100234786A1 (en) * | 2009-02-12 | 2010-09-16 | Barry Neil Fulkerson | System and Method for Detection of Disconnection in an Extracorporeal Blood Circuit |
US8535522B2 (en) | 2009-02-12 | 2013-09-17 | Fresenius Medical Care Holdings, Inc. | System and method for detection of disconnection in an extracorporeal blood circuit |
US20110087499A1 (en) * | 2009-10-13 | 2011-04-14 | Nxstage Medical, Inc. | Dialysis treatment planning and cost optimization |
US9545469B2 (en) | 2009-12-05 | 2017-01-17 | Outset Medical, Inc. | Dialysis system with ultrafiltration control |
US11724013B2 (en) | 2010-06-07 | 2023-08-15 | Outset Medical, Inc. | Fluid purification system |
US8936720B2 (en) * | 2010-09-17 | 2015-01-20 | Baxter International Inc. | Drain and fill logic for automated peritoneal dialysis |
US20120071815A1 (en) * | 2010-09-17 | 2012-03-22 | Baxter Healthcare S.A. | Drain and fill logic for automated peritoneal dialysis |
US11433170B2 (en) | 2011-03-23 | 2022-09-06 | Nxstage Medical, Inc. | Dialysis systems, devices, and methods |
US11224684B2 (en) | 2011-03-23 | 2022-01-18 | Nxstage Medical, Inc. | Peritoneal dialysis systems, devices, and methods |
US11717601B2 (en) | 2011-03-23 | 2023-08-08 | Nxstage Medical, Inc. | Dialysis systems, devices, and methods |
US11135348B2 (en) | 2011-03-23 | 2021-10-05 | Nxstage Medical, Inc. | Peritoneal dialysis systems, devices, and methods |
US10688234B2 (en) | 2011-03-23 | 2020-06-23 | Nxstage Medical, Inc. | Peritoneal dialysis systems, devices, and methods |
US10688235B2 (en) | 2011-03-23 | 2020-06-23 | Nxstage Medical, Inc. | Peritoneal dialysis systems, devices, and methods |
US10046100B2 (en) | 2011-03-23 | 2018-08-14 | Nxstage Medical, Inc. | Peritoneal dialysis systems, devices, and methods |
US10603424B2 (en) | 2011-03-23 | 2020-03-31 | Nxstage Medical, Inc. | Peritoneal dialysis systems, devices, and methods |
US9907897B2 (en) | 2011-03-23 | 2018-03-06 | Nxstage Medical, Inc. | Peritoneal dialysis systems, devices, and methods |
US10610630B2 (en) | 2011-03-23 | 2020-04-07 | Nxstage Medical, Inc. | Peritoneal dialysis systems, devices, and methods |
US11433169B2 (en) | 2011-03-23 | 2022-09-06 | Nxstage Medical, Inc. | Dialysis systems, devices, and methods |
US11690941B2 (en) | 2011-03-23 | 2023-07-04 | Nxstage Medical, Inc. | Peritoneal dialysis systems, devices, and methods |
US10898630B2 (en) | 2011-03-23 | 2021-01-26 | Nxstage Medical, Inc. | Peritoneal dialysis systems, devices, and methods |
US10967112B2 (en) | 2011-04-29 | 2021-04-06 | Medtronic, Inc. | Adaptive system for blood fluid removal |
US11759557B2 (en) | 2011-04-29 | 2023-09-19 | Mozarc Medical Us Llc | Adaptive system for blood fluid removal |
US20130006171A1 (en) * | 2011-06-29 | 2013-01-03 | Fresenius Medical Care Deutschland Gmbh | Dialysis machine |
US10159776B2 (en) * | 2011-06-29 | 2018-12-25 | Presenius Medical Care Deutschland Gmbh | Dialysis machine |
US20130056418A1 (en) * | 2011-09-01 | 2013-03-07 | Fresenius Medical Care Deutschland Gmbh | Dialysate flow control |
US9724455B2 (en) * | 2011-09-01 | 2017-08-08 | Fresenius Medical Care Deutschland Gmbh | Dialysate flow control |
US9328969B2 (en) | 2011-10-07 | 2016-05-03 | Outset Medical, Inc. | Heat exchange fluid purification for dialysis system |
US9861733B2 (en) | 2012-03-23 | 2018-01-09 | Nxstage Medical Inc. | Peritoneal dialysis systems, devices, and methods |
CN104380296A (en) * | 2012-05-15 | 2015-02-25 | 巴克斯特国际公司 | Home medical device systems and methods for therapy prescription and tracking, servicing and inventory |
US10089443B2 (en) * | 2012-05-15 | 2018-10-02 | Baxter International Inc. | Home medical device systems and methods for therapy prescription and tracking, servicing and inventory |
US20130310726A1 (en) * | 2012-05-15 | 2013-11-21 | Baxter Healthcare S.A. | Home Medical Device Systems and Methods for Therapy Prescription and Tracking, Servicing and Inventory |
US9582164B2 (en) | 2012-08-31 | 2017-02-28 | Gambro Lundia Ab | Dialysis apparatus with versatile user interface and method and computer program therefor |
EP2892584B1 (en) * | 2012-09-04 | 2017-06-14 | Fresenius Medical Care Deutschland GmbH | Blood treatment apparatus with a device for quantifying and displaying a time buffer of a patient |
US10755818B2 (en) | 2012-09-04 | 2020-08-25 | Fresenius Medical Care Deutschland Gmbh | Apparatus for quantifying and displaying a patient's time buffer, blood treatment apparatus and method |
US9977868B2 (en) | 2012-09-04 | 2018-05-22 | Fresenius Medical Care Deutschland Gmbh | Apparatus for quantifying and displaying a patient's time buffer, blood treatment apparatus and method |
US11525798B2 (en) | 2012-12-21 | 2022-12-13 | Fresenius Medical Care Holdings, Inc. | Method and system of monitoring electrolyte levels and composition using capacitance or induction |
US9157786B2 (en) | 2012-12-24 | 2015-10-13 | Fresenius Medical Care Holdings, Inc. | Load suspension and weighing system for a dialysis machine reservoir |
US11187572B2 (en) | 2012-12-24 | 2021-11-30 | Fresenius Medical Care Holdings, Inc. | Dialysis systems with a suspended reservoir |
US10539450B2 (en) | 2012-12-24 | 2020-01-21 | Fresenius Medical Care Holdings, Inc. | Load suspension and weighing system for a dialysis machine reservoir |
US9354640B2 (en) | 2013-11-11 | 2016-05-31 | Fresenius Medical Care Holdings, Inc. | Smart actuator for valve |
US10019020B2 (en) | 2013-11-11 | 2018-07-10 | Fresenius Medical Care Holdings, Inc. | Smart actuator for valve |
US10817004B2 (en) | 2013-11-11 | 2020-10-27 | Fresenius Medical Care Holdings, Inc. | Valve system with a pressure sensing displacement member |
JP7167083B2 (en) | 2014-04-08 | 2022-11-08 | フレゼニウス メディカル ケア ドイッチェランド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Prediction method of duration of peritoneal dialysis treatment |
JP2017513666A (en) * | 2014-04-08 | 2017-06-01 | フレゼニウス メディカル ケアー ドイチュラント ゲゼルシャフト ミット ベシュレンクテル ハフツングFresenius Medical Care Deutschland GmbH | Prediction method of treatment duration of peritoneal dialysis treatment |
JP2020127749A (en) * | 2014-04-08 | 2020-08-27 | フレゼニウス メディカル ケア ドイッチェランド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Process for estimation of treatment duration of peritoneal dialysis treatment |
WO2015154859A1 (en) * | 2014-04-08 | 2015-10-15 | Fresenius Medical Care Deutschland Gmbh | Method for estimating the duration of a peritoneal dialysis treatment |
US9579440B2 (en) | 2014-04-29 | 2017-02-28 | Outset Medical, Inc. | Dialysis system and methods |
US9504777B2 (en) | 2014-04-29 | 2016-11-29 | Outset Medical, Inc. | Dialysis system and methods |
US11305040B2 (en) | 2014-04-29 | 2022-04-19 | Outset Medical, Inc. | Dialysis system and methods |
US9402945B2 (en) | 2014-04-29 | 2016-08-02 | Outset Medical, Inc. | Dialysis system and methods |
US11420014B2 (en) | 2015-07-20 | 2022-08-23 | Roivios Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
US11896785B2 (en) | 2015-07-20 | 2024-02-13 | Roivios Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
US11752300B2 (en) | 2015-07-20 | 2023-09-12 | Roivios Limited | Catheter device and method for inducing negative pressure in a patient's bladder |
US11612714B2 (en) | 2015-07-20 | 2023-03-28 | Roivios Limited | Systems and methods for inducing negative pressure in a portion of a urinary tract of a patient |
US11541205B2 (en) | 2015-07-20 | 2023-01-03 | Roivios Limited | Coated urinary catheter or ureteral stent and method |
US11918754B2 (en) | 2015-07-20 | 2024-03-05 | Roivios Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
US11904113B2 (en) | 2015-07-20 | 2024-02-20 | Roivios Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
US11904121B2 (en) | 2015-07-20 | 2024-02-20 | Roivios Limited | Negative pressure therapy system |
US11471583B2 (en) * | 2015-07-20 | 2022-10-18 | Roivios Limited | Method of removing excess fluid from a patient with hemodilution |
US20180311428A1 (en) * | 2015-10-20 | 2018-11-01 | Fresenius Medical Care Deutschland Gmbh | Blood treatment device and method of preparing a prescription |
US11058512B2 (en) * | 2015-12-21 | 2021-07-13 | Fresenius Medical Care Deutschland Gmbh | Sensor-controlled display output for dialysis machines |
US11955234B2 (en) * | 2016-06-30 | 2024-04-09 | Gambro Lundia Ab | Extracorporeal blood treatment system and method including modifiable settings |
US10537673B2 (en) | 2016-08-10 | 2020-01-21 | Medtronic, Inc. | Intersession adaptive peritoneal dialysis fluid removal for multiple session optimization |
US11883576B2 (en) | 2016-08-10 | 2024-01-30 | Mozarc Medical Us Llc | Peritoneal dialysis intracycle osmotic agent adjustment |
US10994064B2 (en) | 2016-08-10 | 2021-05-04 | Medtronic, Inc. | Peritoneal dialysate flow path sensing |
US10874790B2 (en) | 2016-08-10 | 2020-12-29 | Medtronic, Inc. | Peritoneal dialysis intracycle osmotic agent adjustment |
US10758659B2 (en) | 2016-08-10 | 2020-09-01 | Medtronic, Inc. | Peritoneal dialysis filtrate sampling and adaptive prescription |
US10744253B2 (en) | 2016-08-10 | 2020-08-18 | Medtronic, Inc. | Adaptive peritoneal dialysis intra-session adjustments for overall session optimization |
EP3281655A1 (en) * | 2016-08-10 | 2018-02-14 | Medtronic Inc. | Intersession adaptive peritoneal dialysis fluid removal for multiple session optimization |
US11534537B2 (en) | 2016-08-19 | 2022-12-27 | Outset Medical, Inc. | Peritoneal dialysis system and methods |
US11679186B2 (en) | 2016-09-09 | 2023-06-20 | Mozarc Medical Us Llc | Peritoneal dialysis fluid testing system |
US11013843B2 (en) | 2016-09-09 | 2021-05-25 | Medtronic, Inc. | Peritoneal dialysis fluid testing system |
US20180162230A1 (en) * | 2016-12-09 | 2018-06-14 | Mitsubishi Jidosha Kogyo Kabushiki Kaisha | Power source control device and power source control method |
US11393565B2 (en) | 2016-12-21 | 2022-07-19 | Baxter International Inc. | Medical fluid delivery system including a mobile platform for patient engagement and treatment compliance |
US11696977B2 (en) | 2016-12-21 | 2023-07-11 | Baxter International Inc. | Medical fluid delivery system including remote machine updating and control |
US10589014B2 (en) | 2016-12-21 | 2020-03-17 | Baxter International Inc. | Medical fluid delivery system including remote machine updating and control |
US10905811B2 (en) | 2016-12-21 | 2021-02-02 | Baxter International Inc. | Medical fluid delivery system including remote machine updating and control |
US11458232B2 (en) | 2016-12-21 | 2022-10-04 | Baxter International Inc. | Medical fluid delivery system including remote machine updating and control |
US11872337B2 (en) | 2018-02-28 | 2024-01-16 | Nxstage Medical, Inc. | Fluid preparation and treatment devices methods and systems |
US11207454B2 (en) | 2018-02-28 | 2021-12-28 | Nxstage Medical, Inc. | Fluid preparation and treatment devices methods and systems |
US11364328B2 (en) | 2018-02-28 | 2022-06-21 | Nxstage Medical, Inc. | Fluid preparation and treatment devices methods and systems |
US11806457B2 (en) * | 2018-11-16 | 2023-11-07 | Mozarc Medical Us Llc | Peritoneal dialysis adequacy meaurements |
US20200155748A1 (en) * | 2018-11-16 | 2020-05-21 | Medtronic, Inc. | Peritoneal dialysis adequacy meaurements |
US11806456B2 (en) * | 2018-12-10 | 2023-11-07 | Mozarc Medical Us Llc | Precision peritoneal dialysis therapy based on dialysis adequacy measurements |
US20200179583A1 (en) * | 2018-12-10 | 2020-06-11 | Medtronic, Inc. | Precision peritoneal dialysis therapy based on dialysis adequacy meaurements |
US11850344B2 (en) | 2021-08-11 | 2023-12-26 | Mozarc Medical Us Llc | Gas bubble sensor |
US11951241B2 (en) | 2022-11-28 | 2024-04-09 | Outset Medical, Inc. | Peritoneal dialysis system and methods |
Also Published As
Publication number | Publication date |
---|---|
EP2411069A1 (en) | 2012-02-01 |
EP2957305B1 (en) | 2020-11-04 |
CN102361657A (en) | 2012-02-22 |
US20180207339A1 (en) | 2018-07-26 |
EP2411069B1 (en) | 2015-07-22 |
EP2957305A1 (en) | 2015-12-23 |
US10722634B2 (en) | 2020-07-28 |
WO2010108955A1 (en) | 2010-09-30 |
CN102361657B (en) | 2015-12-16 |
ES2548570T3 (en) | 2015-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10722634B2 (en) | Dialysis device | |
EP2618864B1 (en) | Obtaining control settings for a dialysis machine | |
US9700661B2 (en) | Chronic pH or electrolyte monitoring | |
US9050421B2 (en) | Follow-up of the vascular access of a dialyzed patient | |
US10485912B2 (en) | Extracorporeal blood treatment system for individualized treatment | |
US9155823B2 (en) | Determining dialysis treatment effectiveness | |
CN107754034A (en) | For the method and system determined after the dialysis of dry weight | |
EP3635730A1 (en) | Personalized renal failure chronic care systems and methods | |
US20170290969A1 (en) | Method and apparatus for predicting one or more parameters characteristic for the outcome of a blood treatment | |
US20240042110A1 (en) | Vessel Analysis-Based Medical System for Specifying Adjustable Values of a Blood Treatment Apparatus | |
Traum et al. | Urea Kinetic Modeling for Hemodialysis Prescription in Children | |
JP2023500448A (en) | Medical fluid delivery systems including analytics to manage patient engagement and treatment compliance | |
Blanchette et al. | Healthcare resource utilization and costs associated with autosomal dominant polycystic kidney disease | |
Ford | THE HISTORY AND DEVELOPMENT OF UREA KINETIC MODELLING |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |